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Background: Down syndrome (DS) is associated with variable intellectual disability and multiple health and psychiatric
comorbidities. The impact of such comorbidities on cognitive outcomes is unknown. We aimed to describe patterns of
physical health and psychiatric comorbidity prevalence, and receptive language ability, in DS across the lifespan, and
determine relationships with cognitive outcomes.
Methods: Detailed medical histories were collected and cognitive abilities measured using standardised tests for 602
individuals with DS from England and Wales (age range 3 months to 73 years). Differences in prevalence rates between
age groups and between males and females were determined using chi-squared or Fisher’s exact tests. In adults, rates
for psychiatric comorbidities were compared to expected population rates using standardised morbidity ratios (SMRs).
Adapted ANCOVA functions were constructed to explore age and sex associations with receptive language ability
across the lifespan, and regression analyses were performed to determine whether the presence of health
comorbidities or physical phenotypes predicted cognitive abilities.
Results: Multiple comorbidities showed prevalence differences across the lifespan, though there were few sex
differences. In adults, SMRs were increased in males and decreased in females with DS for schizophrenia, bipolar
disorder, and anxiety. Further, SMRs were increased in both males and females with DS for dementia, autism,
ADHD, and depression, with differences more pronounced in females for dementia and autism, and in males for
depression. Across the lifespan, receptive language abilities increasingly deviated from age-typical levels, and
males scored poorer than females. Only autism and epilepsy were associated with poorer cognitive ability in
those aged 16–35 years, with no relationships for physical health comorbidities, including congenital heart defects.
Conclusions: Our results indicate the prevalence of multiple comorbidities varies across the lifespan in DS, and in
adults, rates for psychiatric comorbidities show different patterns for males and females relative to expected population
rates. Further, most health comorbidities are not associated with poorer cognitive outcomes in DS, apart from autism
and epilepsy. It is essential for clinicians to consider such differences to provide appropriate care and treatment for
those with DS and to provide prognostic information relating to cognitive outcomes in those with comorbidities.
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Down syndrome (DS), caused by chromosome 21 triplica-
tion, is the most common genetic cause of intellectual dis-
ability (ID), with a UK incidence of approximately one in
1000 live births [1]. DS is associated with a distinct pheno-
type involving many body systems. ID across the lifespan
and the development of dementia in later life are almost uni-
versal in people with DS [2, 3], with a suggested cumulative
incidence of dementia of 95.7% by age 68 [4]. A number of
other health phenotypes are associated with DS, including
short stature, microcephaly, congenital heart defects, endo-
crine disorders (in particular hypothyroidism), higher risk for
infections, and obstructive sleep apnoea [5–10]. DS is also as-
sociated with increased risk for other neurodevelopmental
conditions including autism and attention deficit hyperactiv-
ity disorder (ADHD) [11]. There is however considerable
variability in both health comorbidities and degree of intel-
lectual impairment among people with DS [2, 12], and links
between health comorbidities and cognitive outcomes are
not currently well understood.
Such associations between health comorbidities and
cognitive outcomes may be due to a hypothesised effect of
a health phenotype or comorbidity on cognitive outcomes
(for example, in the typically developing population, con-
genital heart defects have been associated with poorer
cognitive abilities [13]), or shared genetic mechanisms be-
tween health and cognitive phenotypes. Understanding
such associations may be informative for prognosis for
those with DS.
Further, patterns of comorbidity rates in DS may vary
over the lifespan due to improvements in care and treat-
ment and between males and females, and so detailed
up-to-date information is required to inform clinical ser-
vices, individuals, and their families and carers. To pro-
vide a current understanding of health comorbidities,
including psychiatric comorbidities, in individuals with
DS and their potential relationships with cognitive out-
comes, we conducted one of the largest cross-sectional
studies of individuals with DS to date. We focused on
early childhood (i.e., up to age 5) as this is a critical
period for development, and adulthood (i.e., over age 16)
to explore changes associated with ageing. We had two
main aims: firstly to describe patterns of the prevalence
of common health comorbidities across the lifespan, also
considering sex differences in rates for psychiatric co-
morbidities relative to expected general population rates,
and secondly to explore relationships between receptive
language ability and general cognitive abilities with age
and health comorbidities, respectively.
Methods
Participants
Between 2013 and 2016, 605 individuals with a clinical
diagnosis of DS mainly across England and Wales wererecruited via DS support groups, existing participant da-
tabases, care homes, and National Health Service Trust
sites in four age groups: younger children (3 months to
5.5 years), older children (5.5 to 15 years), younger
adults (16 to 35 years), and older adults (36+ years). Age
groups were defined based on previous definitions of life
stages in DS [14]. Clinical diagnosis of DS was con-
firmed genetically using saliva or blood samples where
possible (see Table 1); following DNA extraction,
genome-wide single nucleotide polymorphism genotyp-
ing was performed using an Illumina OmniExpressEx-
ome array (San Diego, CA, USA) at UCL Genomics,
then assembled and visually inspected in GenomeStudio
to confirm the presence of chromosome 21 trisomy, mo-
saicism, or partial trisomy. Three adults aged 36+ were
excluded from further analyses after genetic analysis did
not suggest an additional chromosome 21, leaving 602
participants.
Ethical approval
Ethical approval was obtained for all adults and younger
children from the North West Wales Research Ethics
Committee (13/WA/0194), and for younger and older
children from the Birkbeck College Ethics Committee
(121373 and 151632, respectively). Written informed
consent was obtained from the parents of all children,
from adults where they had capacity to consent, and via
an appointed consultee where adults did not have cap-
acity to consent, in accordance with the UK Mental
Capacity Act 2005.
Demographic information
Participants’ basic demographic information was ob-
tained via parental or carer report. Socioeconomic status
(SES) was determined based on maternal and paternal
occupations, using the highest major group for the two
occupations as classified by the UK Office of National
Statistics standard occupational classification 2010 (pos-
sible score range 1–9 with lower scores representing
higher SES).
Assessment of health phenotypes
Physical measurements
Height, weight, and head circumference were measured
where possible; body mass index (BMI) was calculated
for adults. BMI measurements are not recommended for
use in younger children, so were not calculated for this
group.
Medical histories
Participants’ detailed lifetime medical histories, consist-
ing of current and previous clinical diagnoses, were col-
lected via informant report from caregivers. These were
confirmed with carer-held medical records where
Table 1 Participant demographic information, the prevalence of selected health comorbidities in each age group, and prevalence
comparisons
Younger children
(0–5.5 years)
Older children
(5.5–15 years)
Younger adults
(16–35 years)
Older adults
(36+ years)
Younger adults
vs younger
children
Older adults
vs younger
adults
Demographic
information
Number 115 35 170 282 N/A N/A
Age 2.18 ± 1.13 (3.6 months
to 5 years 1.3 months)
10.63 ± 3.05
(5 years 6.5 months
to 14 years
8.5 months)
25.25 ± 5.46
(16–35 years)
50.21 ± 7.76
(36–73 years)
N/A N/A
Sex Male 62 (53.9%) 16 (45.7%) 83 (48.8%) 153 (54.3%) N/A N/A
Female 53 (46.1%) 19 (54.3%) 87 (51.2%) 129 (45.7%) N/A N/A
Ethnicity White 93 (81.6%) 25 (86.2%) 145 (85.3%) 261 (92.6%) N/A N/A
Black 5 (4.4%) 0 (0.0%) 7 (4.1%) 11 (3.9%) N/A N/A
Asian 6 (5.3%) 0 (0.0%) 8 (4.7%) 6 (2.1%) N/A N/A
Mixed 7 (6.1%) 4 (13.8%) 8 (4.7%) 2 (0.7%) N/A N/A
Other 3 (2.6%) 0 (0.0%) 2 (1.2%) 2 (0.7%) N/A N/A
Parental
socioeconomic
statusa
1 24 (22.6%) 9 (27.3%) 21 (16.0%) 16 (9.5%) N/A N/A
2 47 (44.3%) 14 (42.4%) 55 (42.0%) 66 (39.1%) N/A N/A
3 19 (17.9%) 5 (15.2%) 23 (17.6%) 10 (5.9%) N/A N/A
4 5 (4.7%) 1 (3.0%) 15 (11.5%) 13 (7.7%) N/A N/A
5 4 (3.8%) 2 (6.1%) 8 (6.1%) 36 (21.3%) N/A N/A
6 3 (2.8%) 1 (3.0%) 6 (4.6%) 4 (2.4%) N/A N/A
7 2 (1.9%) 1 (3.0%) 0 (0.0%) 5 (3.0%) N/A N/A
8 1 (0.9%) 0 (0.0%) 2 (1.5%) 9 (5.3%) N/A N/A
9 1 (0.9%) 0 (0.0%) 1 (0.8%) 10 (5.9%) N/A N/A
Missing 9 2 39 113 N/A N/A
DS typea Trisomy
21
93 (96.9%) 26 (96.3%) 157 (95.7%) 250 (96.5%) N/A N/A
Mosaic 2 (2.1%) 0 (0.0%) 4 (2.4%) 6 (2.3%) N/A N/A
Partial
trisomy
1 (1.0%) 1 (3.7%) 3 (1.8%) 3 (1.2%) N/A N/A
Unknown 19 8 6 23 N/A N/A
Physical
measurements
Height (cm) 81.21 ± 9.72 N/A 152.44 ± 10.32 150.11 ± 9.92 N/A N/A
Weight (kg) 11.62 ± 2.80 N/A 69.78 ± 16.14 68.17 ± 16.09 N/A N/A
BMI N/A N/A 30.09 ± 7.01 30.47 ± 7.25 N/A N/A
Head circumference
(cm)
46.02 ± 2.26 50.40 ± 2.15 53.45 ± 2.55 52.57 ± 2.28 N/A N/A
Psychiatric Autism N/A 2 (5.7%) 23 (13.5%) + 7 (2.5%) + N/A OR = 0.16 (0.07,
0.39), Χ(1) =
20.89, p <
0.001b
ADHD N/A 3 (8.6%) 5 (2.9%) + 1 (0.4%) + N/A OR = 0.12 (0.01,
1.01), p = 0.030c
Schizophrenia N/A 0 (0.0%) 1 (0.6%) 3 (1.1%) N/A OR = 1.82 (0.19,
17.61), p =
1.000c
Bipolar disorder N/A 1 (2.9%) 1 (0.6%) 6 (2.1%) N/A OR = 3.67 (0.44,
30.78), p= 0.263c
Depression N/A 0 (0.0%) 21 (12.4%) 52 (18.4%) N/A OR = 1.60 (0.93,
2.77), Χ(1) =
2.90, p = 0.088b
Anxiety N/A 1 (2.9%) 14 (8.2%) 18 (6.4%) N/A OR = 0.76 (0.37,
1.57), Χ(1) =
0.55, p = 0.457b
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Table 1 Participant demographic information, the prevalence of selected health comorbidities in each age group, and prevalence
comparisons (Continued)
Younger children
(0–5.5 years)
Older children
(5.5–15 years)
Younger adults
(16–35 years)
Older adults
(36+ years)
Younger adults
vs younger
children
Older adults
vs younger
adults
Neurological Cerebral palsy 0 (0.0%) 1 (2.9%) 1 (0.6%) 0 (0.0%) p = 1.000c p = 0.376c
Dementia N/A N/A 0 (0.0%) + 90 (31.9%) + N/A Χ(1) = 67.74,
p < 0.001b
Parkinson’s disease N/A N/A 0 (0.0%) 0 (0.0%) N/A N/A
Stroke N/A N/A 0 (0.0%) 2 (0.7%) N/A p = 0.530c
Migraine N/A N/A 2 (1.2%) 2 (0.7%) N/A OR = 0.60 (0.08,
4.30), p = 0.634c
Epilepsy / seizures 5 (4.3%) 5 (14.3%) 17 (10.0%) + 58 (20.6%) + OR = 2.44 (0.88,
6.83), Χ(1) = 3.08,
p = 0.079b
OR = 2.33 (1.31,
4.16), Χ(1) =
8.56, p = 0.003b
Insomnia 0 (0.0%) * 0 (0.0%) 9 (5.3%) * 16 (5.7%) p = 0.012c OR = 1.08 (0.47,
2.49), Χ(1) =
0.03, p = 0.864b
Physical
health
Obstructive sleep apnoea 1 (0.9%) * 2 (5.7%) 27 (15.9%) * + 11 (3.9%) + OR = 21.52 (2.88,
160.81), Χ(1) =
17.45, p < 0.001b
OR = 0.22 (0.10,
0.45), Χ(1) =
19.77, p <
0.001b
Congenital
heart defects
Total 63 (54.8%) 19 (54.3%) 78 (45.9%) + 49 (17.4%) + OR = 0.70 (0.44,
1.13), Χ(1) = 2.17,
p = 0.140b
OR = 0.25 (0.16,
0.38), Χ(1) =
42.66, p <
0.001b
Known
AVSD
49 (42.6%) 12 (34.3%) 36 (21.2%) 9 (3.2%) N/A N/A
Surgery 22 (19.1%) 5 (14.3%) 36 (21.2%) + 6 (2.1%) + OR = 1.14 (0.63,
2.05), Χ(1) = 0.18,
p = 0.674b
OR = 0.08 (0.03,
0.20), Χ(1) =
45.66, p <
0.001b
Recurrent pneumonia 5 (4.3%) 3 (8.6%) 9 (5.3%) 13 (4.6%) OR = 1.23 (0.40,
3.77), Χ(1) = 0.13,
p = 0.717b
OR = 0.87 (0.36,
2.07), Χ(1) =
0.11, p = 0.743b
Coeliac disease 0 (0.0%) 2 (5.7%) 4 (2.4%) 5 (1.8%) p = 0.150c OR = 0.75 (0.20,
2.83), p = 0.734c
Rheumatoid arthritis N/A N/A 0 (0.0%) 6 (2.1%) N/A p = 0.088c
Psoriasis 0 (0.0%) * 0 (0.0%) 7 (4.1%) * 12 (4.3%) p = 0.044c OR = 1.04 (0.40,
2.68), Χ(1) =
0.01, p = 0.944b
Eczema 11 (9.6%) * 6 (17.1%) 2 (1.2%) * 7 (2.5%) OR = 0.11 (0.02,
0.52), Χ(1) =
11.09, p = 0.001b
OR = 2.14 (0.44,
10.41), p =
0.494c
Gout N/A N/A 2 (1.2%) 11 (3.9%) N/A OR = 3.41 (0.75,
15.57), p =
0.144c
Hypothyroid 8 (7.0%) * 3 (8.6%) 52 (30.6%) * + 117 (41.5%)
+
OR = 5.89 (2.68,
12.97), Χ(1) =
23.05, p < 0.001b
OR = 1.61 (1.08,
2.41), Χ(1) =
5.38, p = 0.020b
Hyperthyroid 3 (2.6%) 1 (2.9%) 2 (1.2%) 2 (0.7%) OR = 0.44 (0.07,
2.70), p = 0.396c
OR = 0.60 (0.08,
4.30), p = 0.634c
Diabetes Type 1 0 (0.0%) 0 (0.0%) 1 (0.6%) 3 (1.1%) p = 1.000c OR = 1.82 (0.19,
17.61), p =
1.000c
Type 2 0 (0.0%) 0 (0.0%) 0 (0.0%) + 8 (2.8%) + N/A p = 0.027c
Reflux 39 (33.9%) * 15 (42.9%) 5 (2.9%) * 14 (5.0%) OR = 0.06 (0.02,
0.16), Χ(1) =
50.40, p < 0.001b
OR = 1.72 (0.61,
4.87), Χ(1) =
1.08, p = 0.299b
Leukaemia 0 (0.0%) 1 (2.9%) 4 (2.4%) + 0 (0.0%) + p = 0.150c p = 0.020c
Cancerous solid tumours N/A N/A 0 (0.0%) 1 (0.4%) N/A p = 1.000c
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Table 1 Participant demographic information, the prevalence of selected health comorbidities in each age group, and prevalence
comparisons (Continued)
Younger children
(0–5.5 years)
Older children
(5.5–15 years)
Younger adults
(16–35 years)
Older adults
(36+ years)
Younger adults
vs younger
children
Older adults
vs younger
adults
Vision and
hearing
Vision impairmentsa 27 (23.5%) * 10 (28.6%) 128 (77.6%) * 191 (75.5%) OR = 11.28 (6.41,
19.85), Χ(1) =
80.25, p < 0.001b
OR = 0.89 (0.56,
1.42), Χ(1) =
0.24, p = 0.625b
Cataracts N/A N/A 15 (8.8%) + 76 (27.0%) + N/A OR = 3.81 (2.11,
6.89), Χ(1) =
21.67, p <
0.001b
Glaucoma N/A N/A 0 (0.0%) 4 (1.4%) N/A p = 0.302c
Hearing impairmentsa 32 (27.8%) * 11 (31.4%) 26 (16.4%) * + 74 (29.6%) + OR = 0.51 (0.28,
0.91), Χ(1) = 5.27,
p = 0.022b
OR = 2.15 (1.30,
3.55), Χ(1) =
9.23, p = 0.002b
Otitis media with effusion
(glue ear)
64 (55.7%) * 26 (74.3%) 44 (25.9%) * + 15 (5.3%) + OR = 0.28 (0.17,
0.46), Χ(1) =
25.83, p < 0.001b
OR = 0.16 (0.09,
0.30), Χ(1) =
39.52, p <
0.001b
Values for age and physical measurements show mean ± standard deviation. Parental socioeconomic status (SES) groups are as follows: 1 managers /
directors / senior officials, 2 professional occupations, 3 associate professional and technical occupations, 4 administrative and secretarial occupations, 5
skilled trade occupations, 6 caring, leisure, and other service occupations, 7 sales and customer service occupations, 8 process, plant, and machine
operatives, 9 elementary occupations.
ADHD attention deficit hyperactivity disorder, AVSD atrioventricular septal defect, N/A not applicable, OR odds ratio
* Significant difference in prevalence between younger children and younger adults (p < 0.05), + significant difference in prevalence between younger
adults and older adults (p < 0.05).
a Percentages calculated based on subsamples; for SES and DS type this excluded individuals whose SES / DS type was unknown, for vision
impairments younger adults n = 165 and older adults n = 253, for hearing impairments younger adults n = 159 and older adults n = 250. Where
prevalence is N/A information was not included in medical questionnaire. Values for comparisons give odds ratios (95% CIs; not possible where one cell
equals zero), and statistical comparisons performed using b chi-squared tests or c Fisher’s exact test as appropriate.
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over the telephone with parents for children, and face-
to-face with a relative (37.6% parent, 12.2% other rela-
tive) or paid carer (50.2%) for adults, via a checklist of
conditions (see Table 1). Where possible, medical histor-
ies collected from paid carers were verified with a rela-
tive over the telephone to ensure accurate information
on conditions in early life.
Measures of cognitive ability
Cognitive abilities were assessed using age-appropriate
measures by trained researchers, usually in participants’
homes for adults and using our testing rooms for
children.
Younger children were administered the Mullen Scales
of Early Learning (MSEL) [15] to assess developmental
abilities across five subscales: receptive language, expres-
sive language, visual reception, gross motor, and fine
motor abilities. Receptive language ability scores were
used in lifespan analyses.
Older children were administered the British Picture
Vocabulary Scale 3 (BPVS3) [16] to assess receptive lan-
guage abilities.
Younger and older adults who met vision and hearing
screening thresholds (3/19 on the Kay vision test and a
loud voice on the Whisper test, see Startin et al. [2])
were administered the Kaufmann Brief Intelligence Test2 (KBIT-2) [17]. The KBIT-2 assesses receptive language
verbal abilities and non-verbal abilities. Adults with ad-
equate vision and hearing who were unable to attempt
tasks due to the severity of their cognitive impairment
or presence of dementia were given a score of zero (n =
34, 8.6%). Receptive language verbal ability scores were
used in lifespan analyses.
Statistical analysis
Prevalence rates of health comorbidities were calculated
for each age group. To identify changes in prevalence
across the lifespan, rates were compared between youn-
ger children and younger adults, and between younger
adults and older adults. To identify sex differences in
prevalence, rates for males and females were compared
for younger children, younger adults, and older adults
separately. Prevalence comparisons used chi-squared
tests or Fisher’s exact test as appropriate. These analyses
did not include older children due to the smaller partici-
pant numbers.
For psychiatric comorbidities and dementia, standar-
dised morbidity ratios (SMRs) for adults were estimated
using the indirect method by comparing our observed
prevalence rates to expected UK general population rates
from Prince et al. [18] for dementia and McManus et al.
[19] for other comorbidities. Splitting analysis by sex,
observed and expected rates were calculated in 10-year
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expected rates provided SMRs for comparison between
populations (see Additional file 1: Tables S1a and S1b).
SMR confidence intervals (CIs) were obtained using
exact 95% Poisson CIs.
Age-adjusted z-scores for available raw receptive lan-
guage scores were calculated from the means and stand-
ard deviations given in standardised tables for each
cognitive test. A z-score of 0 corresponds to age-typical
performance, while a z-score of − 1 corresponds to per-
formance one standard deviation below this. Based on
previous findings of significant differences between re-
ceptive language z-scores calculated for the KBIT-2 and
BPVS3, BPVS3 raw scores for older children were first
converted to KBIT-2 verbal raw scores using a linear
interpolation method based on the relationship between
the two scores from a sub-sample of adults who had
completed both tests (r = 0.96, p < 0.001, n = 34) [20].
We therefore used age-typical levels for KBIT-2 verbal
scores to determine z-scores for older children and all
adults, and age-typical levels from the MSEL receptive
language subscale to determine z-scores for younger
children. Adapted ANCOVA functions were then con-
structed across all ages for receptive language z-scores
(n = 523) and for each age group separately for raw re-
ceptive language scores (younger children n = 104, older
children n = 25, younger adults n = 157, older adults n =
237) to determine associations with age and sex, and
their interaction, with associated effect sizes determined
using ηp
2. All analyses used age as a continuous variable
with sex as two groups.
To examine whether the presence of health comor-
bidities (using a threshold of a minimum prevalence
of 10%) or physical phenotypes predicted cognitive
abilities, separate multiple regression analyses were
performed for younger children (n = 99) using mean
MSEL raw scores calculated from subscale raw scores
excluding the gross motor scale (which does not go
beyond 33 months) and younger adults (n = 157)
using KBIT-2 total raw scores (sum of verbal and
non-verbal scores). Raw scores were used due to floor
effects when converting to standardised scores. Ana-
lyses were not performed for older adults due to the
known risk of cognitive decline due to dementia, orTable 2 Significant differences in health comorbidity prevalence be
Males
Younger children—otitis media with effusion 40 (64.5%)
Younger adults—reflux 5 (6.0%)
Older adults—hypothyroidism 55 (35.9%)
Older adults—otitis media with effusion 12 (7.8%)
Results show the prevalence in males and females (n (%)) with results of statistical
and statistical comparisons performed using a chi-squared tests or b Fisher’s exact t
OR odds ratiofor older children due to the smaller participant num-
bers. Hierarchical regression analyses (Enter method)
were conducted. Model 1 contained sex, age (in years
to two decimal places for younger children and full
years for younger adults), and SES. Model 2 added
the health comorbidity or physical phenotype of inter-
est to determine whether a further significant propor-
tion of variance in cognitive ability was explained.
Where a comorbidity or phenotype explained a sig-
nificant proportion of variance, additional regressions
were performed using raw subscale scores separately
in Model 2, to assess specificity of effects.
Analyses were conducted using SPSS, with p < 0.05 in-
dicating statistical significance, aside from SMRs, which
were determined as described above.
Results
Age, sex, ethnicity, physical measurements, and the ob-
served prevalence of health comorbidities for 115 youn-
ger children, 35 older children, 170 younger adults, and
282 older adults are shown in Table 1.
Health comorbidities across the lifespan
Eczema, reflux, hearing impairments, and otitis media with
effusion (glue ear) were reported to be more common in
younger children compared to younger adults, and insomnia,
obstructive sleep apnoea, psoriasis, hypothyroidism, and
vision impairments less common. Autism, ADHD, obstruct-
ive sleep apnoea, congenital heart defects and related surgery,
history of leukaemia, and otitis media with effusion were re-
ported to be more common in younger adults compared to
older adults, and dementia, epilepsy, hypothyroidism, type 2
diabetes, cataracts, and hearing impairments less common
(Table 1).
Sex differences in prevalence rates of health comorbidities
Several statistically significant sex differences in preva-
lence of health comorbidities were observed (Table 2).
Higher rates were reported in males compared to fe-
males for otitis media with effusion in younger children
and older adults, and for reflux in younger adults.
Higher rates were reported in females compared to
males for hypothyroidism in older adults. No other sextween males and females
Females Statistical comparison
24 (45.3%) OR = 2.20 (1.04, 4.65), X(1) = 4.28, p = 0.039a
0 (0.0%) p = 0.026b
62 (48.1%) OR = 0.61 (0.38, 0.98), X(1) = 4.23, p = 0.040a
3 (2.3%) OR = 3.57 (0.99, 12.96), X(1) = 4.23, p = 0.040a
analysis giving odds ratios (95% CIs; not possible where one cell equals zero),
est as appropriate.
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comorbidities (all p > 0.05).
Prevalence of psychiatric comorbidities compared to
population rates
For adults, SMRs indicated rates of dementia, autism,
ADHD, and depression were higher in individuals with
DS compared to population rates. For dementia and aut-
ism, this relationship was significantly more pronounced
for females than males. For depression, this relationship
was significantly more pronounced for males than fe-
males. Schizophrenia, bipolar disorder, and anxiety had
higher rates in males with DS relative to male popula-
tion rates, while these comorbidities had lower rates in
females with DS relative to female population rates
(Table 3).
Receptive language across the lifespan
Figure 1 and Table 4 show relationships between recep-
tive language ability and chronological age, split by sex.
Across all ages, z-scores decreased with age, and overall,
males scored poorer than females. There was no signifi-
cant interaction between age and sex. For younger and
older children, MSEL raw receptive language scores and
BPVS3 raw scores respectively increased with age. In
younger adults, there was no significant relationship be-
tween age and KBIT-2 raw verbal scores, while in older
adults, KBIT-2 raw verbal scores decreased with age. No
groups showed a significant effect of sex or interaction
between age and sex. These results indicate that across
the lifespan, receptive language abilities of individuals
with DS increasingly deviate from age-typical levels.
Within those with DS, these abilities increase in child-
hood, plateau in young adulthood, then decline in older
adulthood (Fig. 1).Table 3 Standardised morbidity ratios (SMRs) comparing
prevalence rates in adults with DS to UK population rates
SMR males SMR females
Autism 6.83 (6.04, 7.69) 17.60 (14.78, 20.67)
ADHD 5.04 (4.06, 6.27) 5.56 (4.50, 6.84)
Schizophrenia 3.67 (3.14, 4.27) 0.49 (0.33, 0.68)
Bipolar disorder 1.22 (1.05, 1.42) 0.79 (0.65, 0.95)
Depression 4.97 (4.66, 5.29) 3.97 (3.72, 4.23)
Anxiety 1.75 (1.61, 1.90) 0.57 (0.50, 0.64)
Dementia 43.33 (41.14, 45.58) 50.52 (48.13, 52.99)
Figures show SMRs (95% CI) adjusted for age and sex. Population rates for
dementia were taken from Prince et al. [18], all other rates taken from
McManus et al. [19]. If the CI for the SMR includes 1, there is no significant
difference in rates for adults with DS and population rates. An SMR lower than
1 indicates the prevalence in adults with DS is lower than UK population rates.
A value higher than 1 indicates the prevalence in adults with DS is higher than
UK population rates. Non-overlapping CIs in SMRs for males and females
indicate a significant sex difference relative to the population difference.
ADHD attention deficit hyperactivity disorderCognitive outcomes associated with health comorbidities
For younger children, mean MSEL raw scores ranged
from 5.00 to 31.75 with a mean of 17.26 (SD = 6.19).
Model 1 explained 72.0% of variance in mean MSEL raw
scores. Increased age was significantly associated with
increased MSEL raw score, while sex and SES were non-
significant predictors (age: unstandardized B = 4.57, 95%
CI (3.93, 5.21), standardised beta = 0.84, p < 0.001). In
Model 2, no physical measurements or health comorbid-
ities reliably explained additional variance in MSEL raw
scores (Table 5).
For younger adults, KBIT-2 total raw scores ranged from 2
to 108, with a mean of 48.04 (SD= 21.41). Model 1 explained
6.6% of variance in KBIT-2 raw scores. Higher SES was sig-
nificantly associated with increased KBIT-2 raw score, while
age and sex were non-significant predictors (SES: unstan-
dardized B=− 3.37, 95% CI (− 5.82, − 0.93), standardised
beta =− 0.25, p= 0.007). In Model 2 only autism and epilepsy
reliably explained additional variance in KBIT-2 raw scores,
with the presence of either comorbidity associated with
poorer scores (Table 6). Assessing relationships for verbal
and non-verbal subscales separately, autism reliably explained
additional variance for both verbal and non-verbal scores
(verbal: total R2 = 0.14, R2 change = 0.06, unstandardized B=
− 11.56, 95% CI (− 19.64, − 3.48), standardised beta =− 0.24,
p= 0.005; non-verbal: total R2 = 0.17, R2 change = 0.13, un-
standardized B=− 7.15, 95% CI (− 10.41, − 3.89), standar-
dised beta =− 0.37, p < 0.001), while epilepsy reliably
explained additional variance for verbal scores only (verbal:
total R2 = 0.12, R2 change = 0.04, unstandardized B=− 10.98,
95% CI (− 20.36, − 1.61), standardised beta =− 0.20, p=
0.022; non-verbal: total R2 = 0.04, R2 change = 0.01, unstan-
dardized B=− 2.27, 95% CI (− 6.28, 1.74), standardised
beta =− 0.10, p= 0.265).
Discussion
We describe the patterns in prevalence rates of multiple
physical health and psychiatric comorbidities associated
with DS across the lifespan. There were few sex differ-
ences in prevalence, though psychiatric comorbidities
showed different patterns between males and females
with DS relative to population sex differences, with
SMRs elevated in males and reduced in females for
schizophrenia, bipolar disorder, and anxiety. SMRs indi-
cated rates that were greatly elevated for dementia and
also increased for neurodevelopmental comorbidities
(autism and ADHD) and depression in both males and
females with DS, though differences were more pro-
nounced in females for dementia and autism, and in
males for depression. Only age in younger children, and
SES, autism, and epilepsy in younger adults, were pre-
dictive of cognitive ability. Given our results, we have
suggested a number of implications for clinical practice
(Table 7).
Fig. 1 Changes in receptive language ability across the lifespan in DS. Lines show performance for males (blue) and females (red), with age-typical performance
(black). The top graph (a) represents receptive language z-scores across the lifespan (males n=271, females n=252), with a value of 0 corresponding to age-
typical performance. The bottom graphs (b-e) represent raw scores coresponding to the z-scores in the top graph, split into scores for younger children (b; males
n=59, females n=45), older children (c; males n=10, females n=15), younger adults (d; males n=80, females n=77), and older adults (e; males n=122,
females n=115). Children with DS develop abilities (b and c) but do so at a slower pace than typically developing children, as reflected by a decrease in z-scores
over childhood (a). Young adults with DS show a plateau in abilities (d), while in older adults with DS there is a decrease in raw scores (e) likely associated with
the development of dementia which results in a further decrease in z-scores (a)
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Rates reported here were largely similar to those re-
ported previously [6–9, 21], though we noted several dif-
ferences; we did not observe a high prevalence of type 1
diabetes [6, 7] or leukaemia [7], and our finding ofTable 4 Associations between receptive language ability and age a
Number (n) Score Age
All age
groups
523 (271 males, 252
females)
− 3.96 ± 1.33 (− 6.54,
0.14)
F(1,519) = 203.99,
ηp2 = 0.28
Younger
children
104 (59 males, 45
females)
17.01 ± 7.38 (4, 36) F(1,100) = 214.01,
ηp
2 = 0.68
Older
children
25 (10 males, 15
females)
62.24 ± 17.48 (33,
106)
F(1,21) = 27.31, p
ηp2 = 0.57
Younger
adults
157 (80 males, 77
females)
33.48 ± 16.30 (2, 82) F(1,153) = 0.02, p
ηp2 < 0.01
Older
adults
237 (122 males, 115
females)
22.22 ± 17.86 (0, 80) F(1,233) = 42.24, p
ηp2 = 0.15
Analyses were performed for receptive language z-scores across all age groups, for
scores for older children, and for KBIT-2 raw verbal scores for younger and older ad
indicated across all ages z-scores decreased with age, and were lower for males com
language scores and BPVS3 raw scores respectively increased with age. In older aduincreased rates of depression in DS compared to popula-
tion rates contrasts with Alexander et al. [6] who found
a lower incidence in DS using primary care data. Finally,
lower rates for epilepsy in younger children contrasts
with previous reports [22], possibly due to improvednd sex and the interaction between age and sex
Sex Age*sex
p < 0.001, F(1,519) = 5.89, p = 0.016,
ηp2 = 0.01
F(1,519) = 2.90, p = 0.089,
ηp2 = 0.01
p < 0.001, F(1,100) = 0.28, p = 0.595,
ηp
2 < 0.01
F(1,100) = 2.05, p = 0.155,
ηp
2 = 0.02
< 0.001, F(1,21) = 3.41, p = 0.079,
ηp2 = 0.14
F(1,21) = 2.65, p = 0.118,
ηp2 = 0.11
= 0.882, F(1,153) = 2.16, p = 0.144,
ηp2 = 0.01
F(1,153) = 1.44, p = 0.232,
ηp2 = 0.01
< 0.001, F(1,233) = 0.75, p = 0.388,
ηp2 < 0.01
F(1,233) = 0.68, p = 0.409,
ηp2 < 0.01
MSEL raw receptive language scores for younger children, for BPVS3 raw
ults. Values for score show mean ± standard deviation (range). Analyses
pared to females. In younger and older children, MSEL raw receptive
lts, KBIT-2 raw verbal scores decreased with age
Table 5 Regression analyses investigating the relationships between health phenotypes and cognitive abilities in younger children
(n = 99)
Total R2 R2 change Unstandardised B (95% CI) Standardised beta p value
Height 0.77 a 0.01 − 0.08 (− 0.22, 0.05) − 0.13 0.216
Weight 0.77 a < 0.01 − 0.05 (− 0.43, 0.33) − 0.02 0.802
Head circumference 0.77 a < 0.01 0.14 (− 0.27, 0.55) 0.05 0.503
Congenital heart defects 0.72 < 0.01 0.34 (− 1.10, 1.78) 0.03 0.639
Congenital heart defects – AVSD only vs none 0.71 b < 0.01 − 0.01 (− 1.58, 1.57) > − 0.01 0.992
Reflux 0.72 < 0.01 − 0.76 (− 2.27, 0.75) − 0.06 0.320
Vision impairments 0.72 < 0.01 0.87 (− 0.88, 2.62) 0.06 0.327
Hearing impairments 0.72 < 0.01 0.21 (− 1.42, 1.84) 0.02 0.799
Otitis media with effusion 0.72 < 0.01 0.66 (− 0.85, 2.16) 0.05 0.389
Sex, age, and a measure of SES were included in Model 1. All results shown give total R2 for Model 2, R2 change from Model 1, unstandardized B (95% CI),
standardised beta, and p value for each health phenotype.
AVSD atrioventricular septal defect
a Model 1 included age at physical measurement rather than age at medical history telephone interview
b variance explained by Model 1 smaller than for other comorbidities due to a smaller sample; those with a congenital heart defect other than AVSD were
excluded from analysis.
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sampling bias cannot be excluded with parents less will-
ing to participate if children have a severe health
condition.
Similar to our results, previous studies have re-
ported increased rates of dementia, epilepsy,
hypothyroidism, cataracts, and hearing loss with in-
creased age in individuals with DS [6, 21, 23], and an
increased prevalence of otitis media with effusion and
congenital heart defects in younger individuals [24,
25]. The change in prevalence across the lifespan forTable 6 Regression analyses investigating the relationships between
(n = 157)
Total R2 R2 chang
Height 0.07 < 0.01
Weight 0.07 < 0.01
BMI 0.07 < 0.01
Head circumference 0.07 < 0.01
Autism 0.15 0.09
Depression 0.08 0.01
Epilepsy 0.10 0.03
Obstructive sleep apnoea 0.07 < 0.01
Congenital heart defects 0.09 0.02
Congenital heart defects—AVSD only vs none 0.12 a 0.03
Hypothyroid 0.07 < 0.01
Vision impairments 0.07 < 0.01
Hearing impairments 0.07 < 0.01
Otitis media with effusion 0.08 0.01
Sex, age, and a measure of SES were also included in Model 1. All results shown giv
standardised beta, and p value for each health phenotype.
AVSD atrioventricular septal defect
a Variance explained by Model 1 larger than for other comorbidities due to a smalle
from analysis.some of these comorbidities in part likely reflects the
natural changes associated with development and
ageing.
The increased prevalence of autism, ADHD, and ob-
structive sleep apnoea in younger adults compared to
older adults may reflect increased awareness of these co-
morbidities in younger individuals [10, 11]. For congeni-
tal heart defects and related surgery, and for leukaemia,
the increased rate in younger adults most likely reflects
a cohort effect due to improved care and survival in re-
cent decades.health phenotypes and cognitive abilities in younger adults
e Unstandardised B (95% CI) Standardised beta p value
0.24 (− 0.25, 0.72) 0.11 0.337
0.06 (− 0.19, 0.30) 0.04 0.653
< 0.01 (− 0.59, 0.59) < 0.01 0.995
− 0.54 (− 2.31, 1.23) − 0.06 0.546
− 18.72 (− 29.23, − 8.21) − 0.30 0.001
− 8.19 (− 20.08, 3.70) − 0.13 0.175
− 13.27 (− 25.72, − 0.82) − 0.19 0.037
0.61 (− 9.80, 11.01) 0.01 0.908
6.24 (− 1.31, 13.79) 0.15 0.104
8.09 (− 1.25, 17.43) 0.18 0.089
0.46 (− 7.80, 8.72) 0.01 0.913
4.32 (− 4.63, 13.26) 0.08 0.341
− 2.43 (− 12.57, 7.72) − 0.04 0.636
− 4.70 (− 13.30, 3.89) − 0.10 0.281
e total R2 for Model 2, R2 change from Model 1, unstandardized B (95% CI),
r sample; those with a congenital heart defect other than AVSD were excluded
Table 7 Implications for clinical practice
• Clinical guidance tends to be focussed on the needs of children with
DS, but the pattern of comorbidities varies across the lifespan and
surveillance needs to be adapted accordingly:
o Epilepsy is more common in older adults compared to other age
groups, and this is likely associated with the development of
dementia.
o Obstructive sleep apnoea requires on-going surveillance throughout
the lifespan.
o Thyroid disorders, particularly hypothyroidism, become more
common with ageing.
o Reflux is a common concern in children with DS.
o Hearing and vision problems remain an important consideration
throughout life, but these have different causes at different ages.
▪ For hearing, otitis media with effusion is a common issue in
childhood, while other causes of hearing loss become important
in adulthood.
▪ Vision problems increase across the lifespan, with the increased
occurrence of cataracts in adulthood.
• Unlike in the typically developing population, most mental health
conditions are equally common in males and females, requiring similar
surveillance in both sexes to ensure equitable care.
• Neurodevelopmental disorders such as autism and ADHD are relatively
common and do not show the same sex patterns as in the general
population. These should be included in assessment and treatment
guidance for all individuals.
• To improve cognitive outcomes, a focus on interventions for those
with DS from lower SES families and for those with autism or epilepsy
is required.
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comorbidities
We found few significant differences in prevalence rates
between males and females with DS across the lifespan,
with increased prevalence of otitis media with effusion
in males for younger children and older adults, reflux in
males for younger adults, and hypothyroidism in females
for older adults being the only observed differences. In
comparison with population rates, dementia, autism,
ADHD, and depression were elevated for both males
and females with DS, with this relationship more pro-
nounced in females for dementia and autism, and in
males for depression. Other than for depression, SMRs
suggested higher risk in males with DS, but lower risk in
females with DS, for mental illness compared to their
peers in the general population. These results indicate
altered sex profiles for psychiatric comorbidities in DS
relative to the general population, where autism, ADHD,
and schizophrenia are more common in males [26, 27],
and dementia, bipolar disorder, depression, and anxiety
are more common in females [28, 29]. The prevalence
rates for these comorbidities did not significantly differ
between males and females with DS, suggesting lower
modification of risk by sex-related factors compared to
that in the general population.
Receptive language across the lifespan
We explored changes in receptive language ability across the
lifespan in DS using both age-adjusted z-scores and raw
scores. Using z-scores to compare to age-typicalperformance, we found evidence for an increasing divergence
from age-typical performance across the lifespan in DS.
Examining raw scores showed increases in scores for youn-
ger and older children, a plateau in scores for younger adults,
and a decrease in scores for older adults, indicating that the
deviation from age-typical performance in children is driven
by slower development while decline in ability occurs in
older adults, likely associated with the high rates of develop-
ment of dementia. Similarly, Couzens et al. [30] described de-
creases in standardised scores for cognitive abilities as age
increases in those with DS indicating slower development,
with raw scores for multiple cognitive abilities increasing
over childhood and plateauing in early adulthood. We also
found a large degree of variation in ability at any age.
Cognitive outcomes associated with health comorbidities
In younger children, only age contributed to variance in
cognitive ability. In younger adults, SES, autism, and epi-
lepsy contributed to variance in cognitive ability. Simi-
larly, previous studies have reported poorer abilities in
those with DS and autism or epilepsy [11, 31]. The
mechanisms underlying these relationships in DS are
unknown, though it is possible those with multiple neu-
rodevelopmental atypicalities also show an increased vul-
nerability to a more severe ID. Our finding of higher
SES being associated with higher cognitive abilities re-
quires further investigation, and suggests targeting lower
SES families for specific interventions as this relationship
may occur through increased opportunities for those
with higher SES leading to improved cognitive develop-
ment. However, a shared heritability of genes associated
with cognitive abilities cannot be excluded, with parents
of individuals with higher SES being more likely to have
higher IQs.
In contrast to a previous report, we found no relation-
ship between obstructive sleep apnoea and poorer cogni-
tive abilities [32], though we did not conduct detailed
assessments for sleep problems or take account of ob-
structive sleep apnoea severity. We also did not find a
relationship between congenital heart defects and cogni-
tive abilities, suggesting that if appropriately managed,
such defects may have no long-term effects on cognitive
outcomes despite the potentially deleterious effects of
prolonged hospitalisation, anaesthesia, and ischaemic
damage. In the typically developing population, congeni-
tal heart defects have been associated with poorer cogni-
tive abilities [13]. Previous studies in DS have suggested
a similar association in infants and toddlers but not
school-aged children [33, 34]. Additional studies are
needed to further explore this relationship.
Strengths and limitations
The strengths of the current study include its large
community-dwelling sample, cognitive assessments, and
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have recruited approximately 3.5% of younger children
and 1.5% of all adults with DS in England and Wales.
This allowed us to provide important data on the health
comorbidities associated with DS across the lifespan,
which may help clinicians with estimating prognosis and
providing appropriate care.
Limitations include the possible confounding of age ef-
fects with cohort effects, and possible underestimation
of the prevalence of some comorbidities. A longitudinal
or accelerated longitudinal approach would account for
potential cohort effects, taking into account the differ-
ences in health and social care for people with DS over
the decades, which may impact on the development of
certain health conditions. While our study may provide
more accurate estimates of prevalence rates than those
based on hospital or specialist clinic samples (which are
biased towards individuals with more severe conditions),
in common with other community surveys, individuals
with acute conditions (such as children undergoing
treatment for leukaemia) may be under-represented, and
medical histories may become less reliable over time for
older individuals. Although unlikely, it is also possible
that some individuals may have had an undiagnosed
health condition, leading to under-estimates of their
prevalence. In particular, psychiatric comorbidities may
be under-diagnosed and under-recognised in those with
DS, though the UK has specialist mental health services
for those with ID, indicating our figures are likely to be
relatively accurate estimates. Further, if undiagnosed
health conditions were subsequently not treated, they
may have negatively affected cognitive abilities. In
addition, small numbers for some comorbidities resulted
in limited power to detect age and sex variations, though
when comparing psychiatric comorbidity rates in adults
with DS to general population rates, SMRs using the in-
direct method were employed to account for this as is
recommended for rare events. Existing general popula-
tion data were used for these SMR calculations rather
than the collection of new general population data.
These differences in collection methods may not ac-
count for differences in the medical and psychological
attention that individuals with DS and adults in the gen-
eral population receive. However, as the UK has a com-
prehensive National Health Service and specialist mental
health services for individuals with IDs including those
with DS, it is unlikely that this had a significant effect.
Finally, our age groups span a number of years, and lar-
ger sample sizes would allow more specific age group
comparisons to be made.
Future directions
The altered expression of genes on chromosome 21 and
their impact on genomic regulation is thought to be themain factor contributing towards the phenotypes associ-
ated with DS, and likely accounts for the difference in
sex-related psychiatric profiles compared to the general
population. However, due to the variability in pheno-
types, genetic variants within chromosome 21 and other
chromosomes and environmental factors also have a
role. Further, common genetic pathways may influence
multiple phenotypes of DS, or there may be direct rela-
tionships between phenotypes. Identifying the variability
within health comorbidities and factors contributing to-
wards these will help to develop personalised care, and
to identify individuals who may be at risk for specific co-
morbidities to allow for earlier intervention.
Conclusions
We found that multiple comorbidities show variations in
prevalence across the lifespan in DS, and in adults, there
are differences in the rates of psychiatric comorbidities
for males and females relative to expected population
rates, with more pronounced SMRs for dementia and
autism in females, and for depression, schizophrenia, bi-
polar disorder, and anxiety in males. Further, only aut-
ism and epilepsy were found to be associated with
poorer cognitive outcomes in those aged 16–35 years.
Our results provide important information for clinicians
to ensure appropriate care and treatment for those with
DS, including prognostic information relating to cogni-
tive outcomes in those with comorbidities, and we have
provided information on the implications of our findings
for clinical practice.
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